Publications + Posters

| Journal of Medicinal Chemistry

The Discovery of TNG456: A Highly Potent, Selective, Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers

Kevin M. Cottrell, et al.

TNG961: a selective, oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancers

Hilary E. Nicholson, et al.

Hit finding and assay enablement for VRK1, a paralog synthetic lethal kinase target in VRK2-deficient cancers

Katarzyna B. Handing, et al.

Genome-wide CRISPRi screen identifies RPS27 as a novel synthetic lethal target for TP53 mutant cancers

Stephen Paik, et al.

VRK1 inhibition leverages paralog synthetic lethality to selectively target VRK2-deficient cancer cells

Kiera M. Vassallo, et al.

Learn more about our drug discovery programs and explore our pipeline.